Neurol India Home 

Year : 2020  |  Volume : 68  |  Issue : 3  |  Page : 718--719

Contrast-induced Encephalopathy

Mauro Monforte1, Giacomo Della Marca1, Emilio Lozupone2,  
1 Unità Operativa Complessa di Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2 Unità Operativa Complessa di Radiologia e Neuroradiologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy

Correspondence Address:
Dr. Mauro Monforte
Unità Operativa Complessa di Neurologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168, Roma

How to cite this article:
Monforte M, Marca GD, Lozupone E. Contrast-induced Encephalopathy.Neurol India 2020;68:718-719

How to cite this URL:
Monforte M, Marca GD, Lozupone E. Contrast-induced Encephalopathy. Neurol India [serial online] 2020 [cited 2020 Sep 30 ];68:718-719
Available from:

Full Text

A 70-year-old male affected by stage two chronic kidney disease underwent left internal carotid stenting for critical stenosis (contrast agent used: iomeprol). After the procedure, he developed consciousness impairment and myoclonic jerks of the right arm, successfully treated with intravenous (IV) sodium valproate (loading dose IV bolus: 400 mg, continuous infusion rate IV: 50 mg/h). A head computed tomography (CT) scan showed cortical hyperdensity due to contrast leakage in the left frontal lobe [Figure 1]a, without signs of vessel occlusion [Figure 1]b. A full recovery with no further seizures and no neurological deficits was obtained after three days. A follow-up head CT scan ten days after showed a complete normalization of radiological findings [Figure 1]c.{Figure 1}

Contrast-induced encephalopathy (CIE) is a rare complication of procedures requiring intra-arterial injections of iodinated contrast agents, leading to transient and reversible neurological deficits (usually consciousness disturbances, seizures, aphasia, cortical blindness or weakness).[1],[2] CIE incidence is less than 1%, and the timing of onset varies from minutes to hours after the injection of the contrast agent.[3] No clear explanation of the pathophysiological mechanism underlying CIE has been identified, possibly involving direct chemotoxicity on the endothelial vascular cells and osmotic damage of the blood-brain barrier, change in the cerebral hemodynamics (vasoconstriction) or idiosyncratic reaction.[4] The prognosis is generally very good and only a supportive treatment is necessary, for example, for seizures control as in our case. Awareness and identification of CIE is crucial to avoid unnecessary treatment of this usually benign disease.[5]

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Junck L, Marshall WH. Neurotoxicity of radiological contrast agents. Ann Neurol 1983;13:469-84.
2Liao M-T, Lin T-T, Lin L-Y, Hwang J-J, Tseng C-D. Contrast-induced encephalopathy after percutaneous coronary intervention. Acta Cardiol Sin 2013;29:277-80.
3Zhang G, Wang H, Zhao L, Li T, Sun M, Zhang Y, et al. Contrast-induced encephalopathy resulting from use of ioversol and iopromide. Clin Neuropharmacol 2020;43:15-9.
4Wilson AJ, Evill CA, Sage MR. Effects of nonionic contrast media on the blood-brain barrier. Osmolality versus chemotoxicity. Invest Radiol 1991;26:1091-4.
5Molnár L, Fülesdi B, Németh N, Molnár C. Sepsis-associated encephalopathy: A review of literature. Neurol India 2018;66:352-361.